Autotransplantation for relapsed or refractory Hodgkin’s disease: long-term follow-up and analysis of prognostic factors

@article{Lancet1998AutotransplantationFR,
  title={Autotransplantation for relapsed or refractory Hodgkin’s disease: long-term follow-up and analysis of prognostic factors},
  author={JE Lancet and AP Rapoport and Ralph Brasacchio and Shirley W. Eberly and Rf Raubertas and Thomas O. Linder and Amanda Muhs and RE Duerst and CN Abboud and Ch Packman and JF DiPersio and L C Constine and Jm Rowe and JL Liesveld},
  journal={Bone Marrow Transplantation},
  year={1998},
  volume={22},
  pages={265-271}
}
Seventy consecutive patients with refractory or relapsed Hodgkin’s disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine and cyclophosphamide (BEAC). The 5-year Kaplan–Meier event-free survival (EFS) for the entire cohort was 32% (95% confidence interval; 18–45%) with a median follow-up of 3.6… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Bone Marrow Transplant1996;17: 335–340

JK Sont, WAJH van Stiphout, EM Noordijk
  • 1996

Bone Marrow Transplant

R Chopra, AK McMillan, DC Linch
  • 1995